老虎證券

BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

Reuters
昨天
BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

April 21 (Reuters) - Gilead Sciences Inc GILD.O:

  • TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER

  • GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY

  • GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE $(SOC)$ IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

  • GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS

  • GILEAD: OVERALL SURVIVAL $(OS)$, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS

  • GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC

  • GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES

Further company coverage: GILD.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10